Stockscreener 앱 받기
2.45
6.49%
-0.17
시간 외 거래:
2.45
전일 마감가:
$2.62
열려 있는:
$2.51
하루 거래량:
8,281
Relative Volume:
0.09
시가총액:
$11.17M
수익:
-
순이익/손실:
$-2.17M
주가수익비율:
-0.1413
EPS:
-17.3434
순현금흐름:
$-4.82M
1주 성능:
-12.19%
1개월 성능:
-11.23%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.45
$2.54
1주일 범위
$2.45
$2.85
52주 변동 폭
$1.89
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
2.45 | 11.94M | 0 | -2.17M | -4.82M | -17.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Newcelx Ltd 주식(NCEL)의 최신 뉴스
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy - Nasdaq
NewcelX and Eledon join forces to advance potential Type 1 diabetes cure - Indian Pharma Post
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
NewcelX and Eledon partner for NCEL-101 programme - Pharmaceutical Business review -
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
NewcelX Forms Eledon Alliance to Accelerate NCEL-101 Diabetes Program - TipRanks
NewcelX partners with Eledon on type 1 diabetes therapy - Investing.com
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - ChartMill
Should You Buy NewcelX AG (NCEL) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
NLSPW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NCEL | NewcelX Ltd. Ordinary Shares Institutional Ownership - Quiver Quantitative
NCEL | NewcelX Ltd. Ordinary Shares Stock Data, Price & News - Quiver Quantitative
NewcelX Cites Peer-Reviewed Mazindol Data as It Advances CVR-Linked Asset Talks - TipRanks
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - Finviz
NewcelX Updates Corporate Presentation as It Sharpens Focus on Type 1 Diabetes Cell Therapies - TipRanks
NewcelX Announce Positive Results from International Collaborati - GuruFocus
NewcelX Reports Positive International Study Results on Biomaterial-Based Islet Delivery for Type 1 Diabetes - TipRanks
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - marketscreener.com
Newcelx Ltd. Announces Positive Results from International Collaborative Study - marketscreener.com
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewCelX Appoints EY as New Auditor Following Merger - MSN
NewcelX appoints Swiss pharma executive to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX adds Swiss diabetes leader to advisory board to steer IsletRx program - MSN
NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board - marketscreener.com
NewcelX Adds Swiss Diabetes Leader to Advisory Board to Steer IsletRx Program - TipRanks
NewcelX appoints Swiss pharma executive to scientific advisory board - Investing.com
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - Barchart.com
Should I buy NewcelX Ltd. (NCEL) - Zacks Investment Research
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
NewcelX Ltd. (NCEL) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Newcelx Ltd. Share Price (NCEL.US) - London South East
NewcelX Strengthens IP Portfolio with Chinese Patent Publication - TipRanks
NewcelX strengthens IP portfolio with Chinese patent publication - MSN
NewcelX patent for neurological disease treatments published in China - Investing.com
NewcelX patent for neurological disease treatments published in China By Investing.com - Investing.com Canada
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Nasdaq
NCEL|NewcelX Ord Shs|Price:2.690|Chg%:0.02 - TradingKey
NewcelX Ltd. (NCEL) -8.5% in After-hours: Decline Amid Routine Trading Conditions - Stocks Telegraph
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Aktiellt
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) - Aktiellt
NewcelX Ltd.Ordinary Shares (NQ: NCEL - Markets Financial Content
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer) | NLSP SEC FilingForm 6-K - Stock Titan
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
NewcelX appoints ALS specialist to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX appoints ALS specialist to scientific advisory board - Investing.com
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Finviz
NewcelX Appoints Renowned Neurologist to Strengthen Scientific Advisory Board - TipRanks
Newcelx Ltd (NCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):